Update in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares announced by Shareholders Foundation
21. Juni 2016 09:50 ET
|
Shareholders Foundation, Inc.
SAN DIEGO, June 21, 2016 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Massachusetts on behalf of certain purchasers of shares of Aegerion...
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
09. April 2014 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
Deadline on March 17, 2014 in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (AEGR) Shares Announced by Shareholders Foundation
05. Februar 2014 09:35 ET
|
Shareholders Foundation, Inc.
SAN DIEGO, Feb. 5, 2014 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline to get actively involved is coming up on March 17, 2014 in the lawsuit filed on behalf of...
FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)
24. Dezember 2012 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...